Siam Rezwan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Siam Rezwan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ainaz Dory Barkhordarzadeh
David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, United States of America
1 shared publication Aman F. Tahir
David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, United States of America
1 shared publication- Carisa M. Cooney
Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States
1 shared publication Jason Roostaeian
Division of Plastic and Reconstructive Surgery, Department of Surgery, University of California - Los Angeles, Los Angeles, CA, United States of America
1 shared publication- Jose R. Segura-Bermudez
Affiliation David Geffen School of Medicine, University of California, Los Angeles, California, United States of America
1 shared publication - Julia M Dane
DeBusk College of Osteopathic Medicine, Lincoln Memorial University , Harrogate, TN 37752
1 shared publication
Latest Publications
- Open Access
- 16 March 2026
- Published by Elsevier in JPRAS Open
- Vol. 49, 517-528
Aesthetically ideal noses created using a single artificial intelligence model: Validating literature and exploring ethnic differences
- 16 March 2026
- Published by Elsevier in JPRAS Open
- Vol. 49, 517-528
Open AccessAesthetically ideal noses created using a single artificial intelligence model: Validating literature and exploring ethnic differences
- 12 September 2024
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 46 (1) , 14-21
The Fractured Insurance Landscape of Laser Therapy for Scar Revision
Fractional laser therapy improves skin texture, range of motion, and quality of life for patients with traumatic scars. Nevertheless, anecdotal evidence suggests declining insurance coverage for laser therapy. We aimed to characterize the landscape of insurance coverage for fractional laser therapy present our six-year reimbursement trends. We cross-sectionally analyzed the 60 largest American health insurers by enrollee size and market share. For each, we identified their laser therapy policy for scar revision and extracted their documentation, prior, and continuing authorization requirements and treatment guidelines. We also collected retrospective institutional claims data from 2017 to 2022 to investigate trends in reimbursement. Of the 60 largest health insurers, we identified 11 (18.3%) policies on scar revision and 40 policies (66.7%) on reconstructive surgery, including scar revision. Nineteen policies considered laser therapy medically necessary with evidence of functional impairment refractory to prior treatment. Three insurers denied laser coverage under any circumstance. Of the 1,531 claims submitted by our institution for burn scar laser therapy, 13.8% were denied. Patients with Medicare (ORadj, 3.78) or Medicaid (ORadj, 2.80) had significantly greater odds of coverage than privately insured patients (padj, 0.86, p < 0.01). Laser therapy is a powerful treatment that is not widely available to patients with traumatic scars. Our institutional data suggest this access may be further eclipsed by decreasing trends in coverage since 2017. Strategies are needed to protect patient access to this life-changing treatment.
- 12 September 2024
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 46 (1) , 14-21
The Fractured Insurance Landscape of Laser Therapy for Scar Revision
Fractional laser therapy improves skin texture, range of motion, and quality of life for patients with traumatic scars. Nevertheless, anecdotal evidence suggests declining insurance coverage for laser therapy. We aimed to characterize the landscape of insurance coverage for fractional laser therapy present our six-year reimbursement trends. We cross-sectionally analyzed the 60 largest American health insurers by enrollee size and market share. For each, we identified their laser therapy policy for scar revision and extracted their documentation, prior, and continuing authorization requirements and treatment guidelines. We also collected retrospective institutional claims data from 2017 to 2022 to investigate trends in reimbursement. Of the 60 largest health insurers, we identified 11 (18.3%) policies on scar revision and 40 policies (66.7%) on reconstructive surgery, including scar revision. Nineteen policies considered laser therapy medically necessary with evidence of functional impairment refractory to prior treatment. Three insurers denied laser coverage under any circumstance. Of the 1,531 claims submitted by our institution for burn scar laser therapy, 13.8% were denied. Patients with Medicare (ORadj, 3.78) or Medicaid (ORadj, 2.80) had significantly greater odds of coverage than privately insured patients (padj, 0.86, p < 0.01). Laser therapy is a powerful treatment that is not widely available to patients with traumatic scars. Our institutional data suggest this access may be further eclipsed by decreasing trends in coverage since 2017. Strategies are needed to protect patient access to this life-changing treatment.